Rapt Therapeutics Inc (RAPT)

$57.93 +0.01 (0.02%)
Market Cap 1.61B
Revenue (ttm) 0.00
Net Income (ttm) -129.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,171,000
Avg Vol 2,756,486
Day's Range N/A - N/A
Shares Out 27.71M
Stochastic %K 81%
Beta 0.47
Analysts Hold
Price Target $58.00

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its l...

Industry: Biotechnology
Sector: Healthcare
Phone: 650-489-9000
Address:
561 Eccles Avenue, South San Francisco, United States
BillionerOfKing
BillionerOfKing Feb. 21 at 10:37 PM
$RAPT Current Stock Price: $57.91 Contracts to trade: $60.0 RAPT Mar 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 45% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ShannonDavis924
ShannonDavis924 Feb. 21 at 4:56 AM
$RAPT RAPT Therapeutics develops immunology therapies. Clinical data drives valuation. Early-stage risk remains high.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 9:59 PM
$RAPT RSI: 55.42, MACD: 4.1496 Vol: 0.07, MA20: 57.70, MA50: 43.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Fillorkill7
Fillorkill7 Feb. 13 at 3:10 PM
$IMUX samevthing as $$RAPT - big pop after announcement - acquired at a 10x less than a year later.
0 · Reply
gcisme
gcisme Feb. 10 at 10:09 PM
$RAPT @NickEltjes hi 👋
0 · Reply
ClimateBetaX
ClimateBetaX Feb. 4 at 1:40 PM
$RAPT is a biotech focused on inflammatory diseases and oncology; its lead candidate shows promise in atopic dermatitis, but it faces a crowded competitive landscape.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 29 at 9:42 PM
$RAPT RSI: 90.93, MACD: 6.8181 Vol: 12.52, MA20: 42.75, MA50: 36.91 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Dave2468999077844
Dave2468999077844 Jan. 23 at 2:25 PM
$GANX $RAPT https://unusualwhales.substack.com/p/from-73-to-536-overnight-on-rapt?r=27vbi&utm_medium=ios&shareImageVariant=overlay&triedRedirect=true
0 · Reply
Quater2aDolla
Quater2aDolla Jan. 22 at 3:21 PM
$RAPT $SLS change wait to buy and the answer is yes
0 · Reply
WangSLO
WangSLO Jan. 22 at 3:18 PM
$RAPT one year ago was at 9, today is at 50. Are you guys willing to wait a year for $SLS
5 · Reply
Latest News on RAPT
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

Jan 27, 2026, 2:16 PM EST - 27 days ago

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

PEN

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

Jan 20, 2026, 2:13 PM EST - 4 weeks ago

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

GSK

RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition

Jan 20, 2026, 7:32 AM EST - 4 weeks ago

RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition

GSK to buy food allergy drug maker RAPT in $2.2bn deal

Jan 20, 2026, 7:20 AM EST - 4 weeks ago

GSK to buy food allergy drug maker RAPT in $2.2bn deal

GSK

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.

Jan 20, 2026, 7:10 AM EST - 4 weeks ago

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.

GSK to buy RAPT Therapeutics for $2.2 billion

Jan 20, 2026, 2:11 AM EST - 4 weeks ago

GSK to buy RAPT Therapeutics for $2.2 billion

GSK

RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 8:45 PM EST - 5 weeks ago

RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 6 weeks ago

RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices

Nov 15, 2025, 7:32 AM EST - 3 months ago

RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 8:00 AM EST - 3 months ago

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

Nov 4, 2025, 4:05 PM EST - 3 months ago

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

Oct 27, 2025, 8:00 AM EDT - 4 months ago

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

Oct 21, 2025, 11:12 PM EDT - 4 months ago

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Oct 21, 2025, 4:01 PM EDT - 4 months ago

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript

Oct 20, 2025, 5:05 PM EDT - 4 months ago

RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 4 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RANI

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

Oct 20, 2025, 8:00 AM EDT - 4 months ago

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

Oct 19, 2025, 8:00 AM EDT - 4 months ago

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

Sep 29, 2025, 5:00 AM EDT - 5 months ago

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 7 months ago

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Jun 23, 2025, 8:00 AM EDT - 8 months ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

Jun 13, 2025, 9:00 AM EDT - 9 months ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

RAPT Therapeutics to Participate in Upcoming Investor Conferences

Jun 4, 2025, 4:05 PM EDT - 9 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025, 8:00 AM EDT - 10 months ago

RAPT Therapeutics Reports First Quarter 2025 Financial Results

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

Apr 15, 2025, 8:00 AM EDT - 11 months ago

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

Jan 6, 2025, 8:00 AM EST - 1 year ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

RAPT Therapeutics Announces $150 Million Private Placement

Dec 23, 2024, 7:10 AM EST - 1 year ago

RAPT Therapeutics Announces $150 Million Private Placement

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

Nov 11, 2024, 10:34 AM EST - 1 year ago

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24, 2024, 6:32 PM EDT - 1 year ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

May 21, 2024, 8:39 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX SAGE TMCI LNAI

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20, 2024, 4:35 AM EDT - 1 year ago

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

RAPT Therapeutics Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Apr 9, 2024, 12:00 PM EDT - 2 years ago

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

VKTX, JANX and these biotech stocks are surging in 2024

Apr 2, 2024, 2:10 AM EDT - 2 years ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX MCRB RVNC

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 26, 2024, 4:00 AM EST - 2 years ago

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

Feb 20, 2024, 8:36 AM EST - 2 years ago

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:41 AM EST - 2 years ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

Feb 20, 2024, 7:30 AM EST - 2 years ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Feb 13, 2024, 8:00 AM EST - 2 years ago

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Nov 27, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

BillionerOfKing
BillionerOfKing Feb. 21 at 10:37 PM
$RAPT Current Stock Price: $57.91 Contracts to trade: $60.0 RAPT Mar 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 45% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ShannonDavis924
ShannonDavis924 Feb. 21 at 4:56 AM
$RAPT RAPT Therapeutics develops immunology therapies. Clinical data drives valuation. Early-stage risk remains high.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 9:59 PM
$RAPT RSI: 55.42, MACD: 4.1496 Vol: 0.07, MA20: 57.70, MA50: 43.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Fillorkill7
Fillorkill7 Feb. 13 at 3:10 PM
$IMUX samevthing as $$RAPT - big pop after announcement - acquired at a 10x less than a year later.
0 · Reply
gcisme
gcisme Feb. 10 at 10:09 PM
$RAPT @NickEltjes hi 👋
0 · Reply
ClimateBetaX
ClimateBetaX Feb. 4 at 1:40 PM
$RAPT is a biotech focused on inflammatory diseases and oncology; its lead candidate shows promise in atopic dermatitis, but it faces a crowded competitive landscape.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 29 at 9:42 PM
$RAPT RSI: 90.93, MACD: 6.8181 Vol: 12.52, MA20: 42.75, MA50: 36.91 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Dave2468999077844
Dave2468999077844 Jan. 23 at 2:25 PM
$GANX $RAPT https://unusualwhales.substack.com/p/from-73-to-536-overnight-on-rapt?r=27vbi&utm_medium=ios&shareImageVariant=overlay&triedRedirect=true
0 · Reply
Quater2aDolla
Quater2aDolla Jan. 22 at 3:21 PM
$RAPT $SLS change wait to buy and the answer is yes
0 · Reply
WangSLO
WangSLO Jan. 22 at 3:18 PM
$RAPT one year ago was at 9, today is at 50. Are you guys willing to wait a year for $SLS
5 · Reply
Breqqswings
Breqqswings Jan. 22 at 2:01 PM
$RAPT mmmmm
0 · Reply
L7_Trading
L7_Trading Jan. 21 at 8:47 PM
Looks like they are going to Halt-Up YGHJ in to Close... YHGJ is breaking out now.. Are they pumping up ticker YHGJ for 400% today!? Its insane what's going on in this crazy market.. Looks like all eyes are going to YHGJ now.. Watching: $RAPT $MLEC $ACRS $ERAS ** ""
0 · Reply
cheating_stock_investor
cheating_stock_investor Jan. 21 at 7:51 PM
$SRRK this is trading like it wants to go the route of $RAPT
0 · Reply
TheInside2028
TheInside2028 Jan. 21 at 11:16 AM
$RANI our team called $RAPT and we are calling a buyout on $RANI with same capitulation and short interest. Be patient folks-not if! fully consolidated
1 · Reply
sujeto
sujeto Jan. 21 at 3:31 AM
$RAPT there are analyzers with high prices at 95, are you holding or selling?
0 · Reply
BayAreaBiotech
BayAreaBiotech Jan. 21 at 12:20 AM
$RAPT I thought the September 2025 development was great but the buyout was an amazing reward for long term investors.
0 · Reply
BayAreaBiotech
BayAreaBiotech Jan. 21 at 12:18 AM
$RAPT This is another example of where patience pays off.
0 · Reply
topstockalerts
topstockalerts Jan. 20 at 11:30 PM
Top Gainers $IVF $CRVS $ACRS $RAPT $YOUL
0 · Reply
fryfinancial
fryfinancial Jan. 20 at 11:23 PM
$RAPT no lies told
0 · Reply
edvquye
edvquye Jan. 20 at 8:23 PM
$RAPT
0 · Reply
topstockalerts
topstockalerts Jan. 20 at 8:03 PM
Top Gainers $IVF $CRVS $ACRS $RAPT $TWG
0 · Reply
sixfigures718
sixfigures718 Jan. 20 at 6:59 PM
$CRVS $IVF $NUAI $OGEN $RAPT
0 · Reply